AAAAAA
Results:
1-7
|
Results: 7
Authors:
Anderson, CP
Seeger, RC
Satake, N
Monforte-Munoz, HL
Keshelava, N
Bailey, HH
Reynolds, CP
Citation: Cp. Anderson et al., Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line, J PED H ONC, 23(8), 2001, pp. 500-505
Authors:
Keshelava, N
Zuo, JJ
Chen, P
Waidyaratne, SN
Luna, MC
Gomer, CJ
Triche, TJ
Reynolds, CP
Citation: N. Keshelava et al., Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines', CANCER RES, 61(16), 2001, pp. 6185-6193
Authors:
Keshelava, N
Grosheu, S
Reynolds, CP
Citation: N. Keshelava et al., Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines, CANC CHEMOT, 45(1), 2000, pp. 1-8
Authors:
Keshelava, N
Zuo, JJ
Waidyaratne, NS
Triche, TJ
Reynolds, CP
Citation: N. Keshelava et al., p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma, MED PED ONC, 35(6), 2000, pp. 563-568
Authors:
Goto, H
Keshelava, N
Matthay, KK
Lukens, JN
Gerbing, RB
Stram, DO
Seeger, RC
Reynolds, CP
Citation: H. Goto et al., Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors, MED PED ONC, 35(6), 2000, pp. 619-622
Authors:
Anderson, CP
Keshelava, N
Satake, N
Meek, WH
Reynolds, CP
Citation: Cp. Anderson et al., Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression, MED PED ONC, 35(6), 2000, pp. 659-662
Authors:
Keshelava, N
Seeger, RC
Groshen, S
Reynolds, CP
Citation: N. Keshelava et al., Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy, CANCER RES, 58(23), 1998, pp. 5396-5405
Risultati:
1-7
|